INH-A21: A donor-selected Staphylococcal human immune globulin for the prevention of late-onset neonatal Staphylococcal infection

Expert Opinion on Investigational Drugs

Volumn 15, Issue 6, 2006, Pages 703-707

  Bloom, Barry T ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

Author keywords

Human immune globulin; Late onset sepsis; Neonate; Staphylococcus

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; GLYCINE; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INH A 21; PLACEBO; POLYSORBATE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ANEMIA; APNEA; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; DIAPER DERMATITIS; DOSE RESPONSE; DRUG FATALITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INFUSION; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HOSPITAL INFECTION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; IN VITRO STUDY; INFECTION PREVENTION; INFECTION RATE; INFECTION RISK; LOW DRUG DOSE; NECROTIZING ENTEROCOLITIS; NEWBORN INFECTION; NONHUMAN; OBSTRUCTIVE JAUNDICE; PREMATURITY; RANDOMIZATION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEPSIS; SKIN DISEASE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VASCULAR ACCESS;

ADHESINS, BACTERIAL; ANIMALS; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT, NEWBORN; INFANT, VERY LOW BIRTH WEIGHT; RANDOMIZED CONTROLLED TRIALS; STAPHYLOCOCCAL INFECTIONS;

EID: 33745288996     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.6.703     Document Type: Article

References (24)

1. PATTI JM, ALLEN BL, McGAVIN MJ, HOOK M: MSCRAMM-mediated adherence of microorganisms to host tissues. Ann. Rev. Microbiol. (1994) 48:585-617.
2. HOOK M, PATTI JM, McGAVIN M et al.: MSCRAMMs - Microbial Recognition Systems for Extracellular Matrix Molecules. In: Molecular Pathogenesis of Surgical Infections, Wadström T (Ed.), Gustav Fischer Verlag, Stuttgart, Germany (1994):137-44.
3. MARTIN JA, HAMILTON BE, VENTURA SJ, MENACKER F, PARK MM: Births: final data for 2000. Natl. Vital. Stat. Rep. (2002) 50(5):1-101.
4. FANAROFF AA, KORONES SB, WRIGHT LL et al.: Incidence, presenting features, risk factors and significance of late onset septicemia in very low birth weight infants. The National Institute of Child Health and Human Development Neonatal Research Network. Pediatr. Infect. Dis. J. (1998) 17(7):593-598.
5. ETZIONI A, OBEDEANU N, BLAZER S, BENDERLY A, MERZBACH D: Effect of an intravenous γglobulin preparation on the opsonophagocytic activity of preterm serum against coagulase-negative staphylococci. Acta Paediatr. Scand. (1990) 79(2):156-161.
6. FUJIWARA T, TANIUCHI S, HATTORI K, KOBAYASHI T, KINOSHITA Y, KOBAYASHI Y: Effect of immunoglobulin therapy on phagocytosis by polymorphonuclear leucocytes in whole blood of neonates. Clin. Exp. Immunol. (1997) 107(3):435-439.
7. STOLL BJ, HANSEN N, FANAROFF AA et al.: Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics (2002) 110(2 Part 1):285-291.
8. STOLL BJ, GORDON T, KORONES SB et al.: Late-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. J. Pediatr. (1996) 129:63:71.
9. STOLL BJ, HANSEN NI, ADAMS-CHAPMAN I et al.: Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. J. Am. Med. Assoc. (2004) 292(19):2357-2365.
10. CDC: Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb. Mortal. Wkly Rep. (2002) 51(26):565-567.
11. GARRETT DO, JOCHIMSEN E, MURFITT K et al.: The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis. Infect. Control. Hosp. Epidemiol. (1999) 20(3):167-170.
12. CHRISTENSEN RD, HARDMAN T, THORNTON J, HILL HR: A randomized, double-blind, placebo-controlled investigation of the safety of intravenous immune globulin administration to preterm neonates. J. Perinatol. (1989) 9:126-130.
13. BAKER CJ, MELISH ME, HALL RT, CASTRO DT, VASAN U, GIVNER LB: Intravenous immune globulin for the prevention of nosocomial infection in low-birth-weight neonates. The Multicenter Group for the Study of Immune Globulin in Neonates. N. Engl. J. Med. (1992) 327(4):213-219.
14. FANAROFF AA, KORONES SB, WRIGHT LL et al.: A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N. Engl. J. Med. (1994) 330(16):1107-1113.
15. JENSEN HB, POLLOCK BH: Meta-analyses of the effectiveness of intravenous immune globulin for prevention and treatment of neonatal sepsis. Pediatrics (1997) 99:E2.
16. LACY JB, OHLSSON A: Administration of intravenous immunoglobulins for prophylaxis or treatment of infection in preterm infants: metaanalyses. Arch. Dis. Child. Fetal. Neonatal Ed. (1995) 72:F151-F155.
17. OHLSSON A, LACY JB: Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants. Cochrane Database Syst. Rev. (2004) 1:CD000361.
18. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis: the PREVENT Study Group. Pediatrics (1997) 99:93-99.
19. BLOOM BT, KUESER TJ, OELBERG DG et al.: A Phase I, multicenter study of safety and tolerance of a donor-selected staphylococcal immune globulin in very low birth weight infants. Pediatric Academic Societies Annual Meeting, Seattle, USA (2003) (Abstract 1804).
20. INHIBITEX, INC.: Investigator's Brochure, INH-A21®, Version 4 (April 29 2005).
21. VERNACHIO JH, BAYER AS, AMES B et al.: Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo. Antimicrob. Agents Chemother. (2006) 50:511-518.
22. CAPPARELLI EV, BLOOM BT, KUESER TJ et al.: Multicenter study to determine antibody concentrations and assess the safety of administration of INH-A21, a donor selected human staphylococcal immune globulin in low-birth-weight infants. Antimicrob. Agents Chemother. (2005) 49(10):4121-4127.
23. BLOOM B, SCHELONKA R, KUESER T et al.: Multicenter study to assess safety and efficacy of INH-A21, a donor selected human staphylococcal immunoglobulin, for prevention of nosocomial infections in very low-birth-weight infants. Pediatr. Infect. Dis. J. (2005) 24(10):858-866.
24. WALSON PD: Patient recruitment: US perspective. Pediatrics (1999) 104(3 Part 2):619-622.